Abstract: The present disclosure relates generally to data storage using DNA sequences comprising synthetic nucleotides. In particular, the disclosure provides for a DNA data storage system comprising a covalently linked sequence of nucleotides, wherein the sequence of nucleotides comprises a modification region, wherein the nucleotides comprise synthetic nucleotides.

Abstract: A drop cable includes a transmission core, a strength member arranged alongside the transmission core and an outer sheath surrounding the transmission core and the strength member. The transmission core comprises two insulated conductors and an optical sub-core comprising six or more optical fibers, the optical sub-core and the insulated metallic conductors being stranded together and surrounded by a sleeve. Moreover, a diameter of the strength member is substantially equal to or higher than a diameter of the transmission core.

Abstract: The invention relates to an aqueous pharmaceutical composition comprising: a) bilastine, or a pharmaceutically acceptable salt or solvate thereof, b) benzalkonium chloride, in combination with at least one further preservative selected from the group comprising phenylethyl alcohol, benzyl alcohol, sodium benzoate, chlorbutanol, phenoxyethanol, cetrimide and 2-(ethylmercuriomercapto)benzoic acid sodium salt, c) a suspending agent, and d) 2-hydroxypropyl-?-cyclodextrin; wherein the pH of the aqueous pharmaceutical composition is between 3.5 and 5.5. The invention also relates to said compositions for use in the treatment and/or prevention of a disorder or disease susceptible to amelioration by antagonism of H1 histamine receptor and/or of a corticosteroid-responsive disease through nasal administration. The invention also relates to a process for preparing the aqueous pharmaceutical composition above mentioned.

Abstract: The invention relates to an aqueous pharmaceutical composition comprising: a) bilastine or a pharmaceutically acceptable salt or solvate thereof, b) mometasone, or a pharmaceutically acceptable derivative thereof, c) a suspending agent, and d) 2-hydroxypropyl-?-cyclodextrin; wherein the pH of the aqueous pharmaceutical composition is between 3.5 and 5.5, and wherein the content of 2-hydroxypropyl-?-cyclodextrin is less than 8.5% by weight. The invention also relates to said compositions for use in the treatment and/or prevention of a disorder or disease susceptible to amelioration by antagonism of H1 histamine receptor and/or of a corticosteroid-responsive disease through nasal administration. The invention also relates to a process for preparing the aqueous pharmaceutical composition above mentioned.

Abstract: The invention relates to new intermediates in the synthesis of Eldecalcitol and to processes for the preparation of said intermediates and of Eldecalcitol.

Abstract: Nick-based methods, devices, and systems for nick-based data storage in a deoxyribonucleic acid (DNA) sequence are disclosed. Digital information is encoded in a register of at least one copy of a double-stranded DNA sequence having a plurality of nickable positions. The data is translated into a sequence of values from a nick alphabet that is subsequently mapped to the plurality of nickable positions, and the DNA sequence is nicked according to the mapped values. Because the digital information is encoded as a series of nicked and non-nicked positions of a double-stranded DNA sequence, the nucleotide sequence of the DNA can be non-synthetic, or “native” DNA.

Abstract: The invention relates to new intermediates in the synthesis of Eldecalcitol and to processes for the preparation of said intermediates and of Eldecalcitol.

Abstract: The invention relates to a process for preparing a compound of (III) wherein X is a leaving group; and R1 is C1-C6 alkyl; which comprises oxidative rearrangement of a compound of formula (II) or a solvate thereof Compounds of formula (III) are key intermediates in the synthesis of Bilastine.

Abstract: The invention relates to compounds of formula (I): or pharmaceutically acceptable sails or solvates thereof, to pharmaceutical compositions comprising them and to their use in the treatment and/or prevention of diseases or disorders mediated by histamine H4 receptor.

Abstract: The invention relates to a process for preparing a compound of (III) wherein X is a leaving group; and R1 is C1-C6 alkyl; which comprises oxidative rearrangement of a compound of formula (II) or a solvate thereof Compounds of formula (III) are key intermediates in the synthesis of Bilastine.

Abstract: The present invention deals with a process for catalytic cracking of hydrocarbons comprising vacuum gas oil, hydrotreated vacuum gas oil, unconventional light crude oil, preferably unconventional light crude oil type shale/tight oil and its blends with conventional vacuum gas oil, in order to generate products of major commercial value in the field of fuels, getting improved gasoline and coke yield, as well as the procedure for the preparation of a catalyst with essential physical properties of density and particle size to uphold it in a fluidized bed under the operation conditions in the catalyst evaluation unit at micro level, wherein the catalyst particles achieve a catalytic performance similar to fluidized microspheres in a reactor, without appreciable generation of fine particles.

Abstract: The present invention relates to a catalytic formulation used in the hydroprocessing of light and middle oil fractions, preferably in hydrodesulfurization and hydrodenitrogenation reactions to obtain diesel with ultra low sulfur content less than or equal to 15 ppm in weight. The catalytic formulation, object of the present invention, consists of at least one metal of Group VI B and at least one metal of Group VIII B and one element of Group V A of the periodic table deposited on a support based on surface modified alumina with an inorganic oxide of a metal of Group II A, IV A and/or IV B. And containing an impregnated organic compound containing at least one hydroxyl group and at least one carboxyl group and that can contain or not at least one sulfide group in its structure. The catalytic formulation, object of the present invention, allows processing of the oil fractions with initial and final boiling temperatures between 150 and 450° C.

Abstract: The invention relates to an aqueous pharmaceutical composition comprising: a) bilastine or a pharmaceutically acceptable salt or solvate thereof, b) mometasone, or a pharmaceutically acceptable derivative thereof, c) a suspending agent, and d) 2-hydroxypropyl-?-cyclodextrin; wherein the pH of the aqueous pharmaceutical composition is between 3.5 and 5.5, and wherein the content of 2-hydroxypropyl-?-cyclodextrin is less than 8.5% by weight. The invention also relates to said compositions for use in the treatment and/or prevention of a disorder or disease susceptible to amelioration by antagonism of H1 histamine receptor and/or of a corticosteroid-responsive disease through nasal administration. The invention also relates to a process for preparing the aqueous pharmaceutical composition above mentioned.

Abstract: The invention relates to an aqueous ophthalmic pharmaceutical composition comprising: a) at least 0.4% w/v of bilastine, of formula or a pharmaceutically acceptable salt or solvate thereof, wherein the bilastine salt or solvate thereof is completely dissolved in the pharmaceutical composition; b) at least one ?-cyclodextrin; and c) at least one pharmaceutically acceptable water-soluble gelling agent; and wherein the pH is comprised between 4 and 9. and its use in the treatment and/or prevention of conditions mediated by H1 histamine receptor, such as allergic disorders or diseases. The invention relates to the treatment and/or prevention of allergic conjunctivitis.

Abstract: The present invention relates to calcifediol soft capsules, to their use in the treatment or prevention of diseases related to vitamin D deficiency, such as vitamin D deficiency, demineralization such as hypocalcemia and hypophosphatemia, renal osteodystrophy, rickets, osteoporosis, osteopenia, osteoarthritis, osteoarthrosis, osteomalacia, hypoparathyroidism, and inflammatory bowel disease, and to their process of manufacture.

Abstract: The present invention is an in-situ cleaning procedure for the recovery of catalytic activity of a based alumina HDS catalyst, molybdenum, nickel coated coke and contaminants and it has an HDS activity seriously diminished. The catalyst under study had between 13 and 18 wt % total carbon. Reformate, half the total volume, industrial toluene=35 volume % and Iso-propylic alcohol, 15 volume %, in order to reactivate a deactivated catalyst, a solvent mixture with the following volumetric ratio is prepared. Or it can also be used only reformate (100% volume). The solvent mixture is passed using a LHSV of 2 hr?1 for 72 hours at 50° C. or also using a recirculating three 24-hour cycles at 50° C. Option lasts 24 hours pure reformate LHSV=2h?1 to 50° C. The washed catalyst is fed back to the load reaction conditions maintained for 36 hours at 340° C., to initiate HDS activity balances. During this treatment oxides of molybdenum and nickel in the active phase are re-sulfided by increasing the HDS activity.

Abstract: The present invention deals with a process for catalytic cracking of hydrocarbons comprising vacuum gas oil, hydrotreated vacuum gas oil, unconventional light crude oil, preferably unconventional light crude oil type shale/tight oil and its blends with conventional vacuum gas oil, in order to generate products of major commercial value in the field of fuels, getting improved gasoline and coke yield, as well as the procedure for the preparation of a catalyst with essential physical properties of density and particle size to uphold it in a fluidized bed under the operation conditions in the catalyst evaluation unit at micro level, wherein the catalyst particles achieve a catalytic performance similar to fluidized microspheres in a reactor, without appreciable generation of fine particles.

Abstract: The present invention is related to formulations consisting of block copolymers ?,?-di-aryl or alkyl sulfonates of poly(ethylene oxide)w-poly(propylene oxide)-poly(ethylene oxide)w of bis-ammonium and block copolymers ?,?-di-amine of poly(ethylene oxide)w-poly(propylene oxide)-poly(ethylene oxide)w, that are effective in the dewatering and desalting crude whose specific gravities are within the range of 14 to 23°API.

Abstract: The invention relates to a stable supersaturated aqueous solution comprising bilastine and an selected from glutaric acid, citric acid, ?-cetoglutaric acid, tartaric acid, acetic acid, propionic acid and mixtures thereof and to its use in the treatment and/or prevention of conditions mediated by H1 histamine receptor, such as allergic disorders or diseases. The invention also relates to the use of the above organic carboxylic acids to increase the aqueous solubility of bilastine.

Abstract: A chemical synthesis process is provided for the functionalization of monodispersed triblock copolymer (POEw-POPy-POEw) with secondary or tertiary amines at a semi-industrial level in glass reactors having a capacity between 1 L and 100 L. The process includes two stages where the first stage uses an alkylsulfonyl or arylsulfonyl chloride to obtain better leaving groups, and the second stage is the nucleophilic substitution with secondary or tertiary amines, to obtain the bifunctionalized triblock copolymers. The main advantage for this process is to reduce the quantity of unitary process done in each stage, the optimization of reaction times, and the stoichiometric relationships.